Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs).
Synaffix revenues and margins will be recognized within the Lonza business from the date of acquisition.
Lonza is paying about $107 million (100 million euros) in cash to acquire Synaffix, with up to $64 million in “additional performance-based consideration” on the table.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze